Mauna Kea Technologies welcomes Jacquelien ten Dam to Board of Directors
Mauna Kea Technologies announced today the cooptation by the Board of Ms. Jacquelien ten Dam as an Independent Director, effective immediately. Ms. ten Dam replaces Dr. Jennifer Tseng, who tendered her resignation from the Board after 3 years of service. This cooptation will be subject to the approval of the Ordinary General Meeting of Mauna Kea Technologies, which will be voting on the financial statements for the fiscal year ending December 31, 2020, to be held in 2021.
“On behalf of the Board of Directors, I would like to thank Jennifer for her important contribution to the Mauna Kea Board,” stated Sacha Loiseau, Ph.D., Founder and Chairman of the Board of Directors of Mauna Kea Technologies. “It has been a pleasure to work with Jennifer and we have benefitted greatly from her expertise as a surgeon and clinical leader.”
Mr. Loiseau continued, “Likewise, I am pleased to welcome Jacquelien to the Board, where she will bring more than a decade of experience advising, financing and leading innovative European healthcare firms. Jacquelien’s expertise will be important as the Company accelerates the commercialization of the Cellvizio platform and executes on its strategic roadmap.” Ms. ten Dam currently serves as the Chief Financial Officer of Mimetas, a biotech company based in The Netherlands.
“My experience with Mauna Kea precedes the Company’s 2011 IPO and I remain impressed with the far-reaching potential of Cellvizio to improve patient care and advance science,” commented Jacquelien ten Dam. “I look forward to contributing to the Company’s next phase of value creation for Mauna Kea shareholders.”
Jacquelien ten Dam studied Biomedical Sciences before joining Kempen, a leading European investment bank, where she advised life science firms on strategy, M&A and capital market transactions. After a stint at Picnic, a start-up company in the digital retail industry, Jacquelien joined Mimetas as Chief Financial Officer. Mimetas develops and commercializes 3D predictive models for drug discovery.
